Japan CAR‐T Cell Therapies Market Overview 2025-2033: Size, CAGR, PMDA Support & Sakigake Path - Japan Insights

The Japan CAR-T Cell Therapies Market reached US$ 346.00 million in 2024 and is expected to reach US$ 1,350.15 million by 2033, growing at a CAGR of 16.3% during the forecast period 2025-2033.

Latest News (May-June 2025) Japan CAR‐T infrastructure, regulatory support, and clinical innovation:

Kyushu Univ biomarker boosts CAR‐T safety

Researchers developed CSF-based protein biomarkers to predict neurotoxicity (ICANS), which could enable safer CAR‐T use in B-cell non-Hodgkin's lymphoma

Cellares & Mitsui Fudosan to build automated CAR‐T factory
A new smart cell therapy manufacturing plant in Chiba will begin commercial-scale CAR‐T and cell therapy production in 2026, boosting local supply chains

Nagoya Univ gene tweak improves CAR‐T durability
Suppressing the CUL5 gene in CD19-targeted CAR‐T cells appears to extend their effectiveness, reducing relapse risk in leukemia/lymphoma models

NCC spin‐out readies first CAR‐T for adult T‐cell leukemia trial
ARC Therapies plans clinical enrollment in 2026 for its ATLL-targeted CAR‐T therapy, derived from Japan's National Cancer Center

Unlock exclusive insights with our detailed sample report (Corporate Email ID gets priority access): https://datamintelligence.com/download-sample/japan-car-t-cell-therapies-market?kb

Japan CAR-T Cell TherapiesMarket Overview

Japan CAR‐T cell therapies refer to the development, approval, manufacturing, and clinical use of chimeric antigen receptor T‐cell (CAR‐T) therapies within Japan's healthcare ecosystem. These therapies involve genetically modifying a patient's own T-cells to target and destroy cancer cells, particularly in blood cancers such as leukemia, lymphoma, and multiple myeloma.

Japan's CAR‐T cell Market is shaped by:

Innovative regulatory frameworks, including PMDA's Sakigake designation and conditional early approvals for regenerative medicine.

Collaborations between biopharma companies and Japanese institutions.

A growing network of advanced manufacturing and hospital-based infusion centers.

CAR‐T therapy in Japan is gaining traction due to rising cancer incidence, increasing demand for personalized medicine, and strategic government support for cell and gene therapies.

Research Methodology:

The Japan CAR-T Cell Therapies Market research report is based on a combination of primary and secondary data sources. The study carefully analyzes various factors influencing the industry, including government regulations, market dynamics, competitive landscape, historical trends, current conditions, and technological progress. It also evaluates future developments, related industry trends, market volatility, growth prospects, potential obstacles, and emerging challenges.

Segment Covered in the Japan CAR-T Cell Therapies Market:

By Therapy Type: Autologous CAR-T Cell Therapy, Allogeneic CAR-T Cell Therapy

By Drug Type: Abecma, Breyanzi, Carvykti, Tecartus, Kymriah, Yescarta

By Target Antigen: CD19, BCMA (B-cell maturation antigen), CD20, CD22, CD30, Others

By Application: Acute Lymphoblastic Leukemia (ALL), Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Multiple Myeloma (MM), Follicular Lymphoma, Others

Speak to Our Analyst and Get Customization in the report as per your requirements: https://datamintelligence.com/customize/japan-car-t-cell-therapies-market?kb

List of the Key Players in the Japan CAR-T Cell Therapies Market:

Gilead Sciences, Inc., Bristol Myers Squibb Company, Johnson & Johnson Services, Inc., and Novartis AG, among others.

Industry Development:

In April 2024, Johnson & Johnson announced that the U.S. FDA had approved CARVYKTI (ciltacabtagene autoleucel; cilta-cel) for adult patients with relapsed or refractory multiple myeloma. This approval applies to individuals who have previously undergone at least one line of therapy, including a proteasome inhibitor and an immunomodulatory agent, and who are refractory to lenalidomide.

In January 2024, Bristol Myers Squibb reported that its CAR-T therapy Breyanzi (lisocabtagene maraleucel) received regulatory acceptance from both the U.S. FDA and Japan's Ministry of Health, Labour and Welfare (MHLW), advancing its expansion.

In April 2023, Takara Bio Inc. filed a Clinical Trial Application (CTA) with Health Canada and received a No Objection Letter to initiate a Phase I/Ib clinical trial for its CD19 JAK/STAT CAR-T therapy (TBI-2001). The trial, led by investigators, will begin once all required steps are completed, targeting patients with CD19-positive B-cell lymphoma.

The Report Includes:

➡ A descriptive analysis of demand-supply gap, market size estimation, SWOT analysis, PESTEL Analysis and forecast in the market.

➡ Top-down and bottom-up approach for regional analysis

➡ Go-to-market Strategy.

➡ Neutral perspective on the market performance.

➡ Customized regional/country reports as per request and country level analysis.

➡ Potential & niche segments and regions exhibiting promising growth covered.

People Also Ask:

➠ What are the sales, production, consumption, imports, and exports in the Japan CAR-T Cell Therapies market?

➠ Who are the top manufacturers, and what are their capacity, production, sales, pricing, and revenue stats?

➠ What key opportunities and challenges do vendors face in the Japan CAR-T Cell Therapies industry?

➠ Which product types, applications, or end-users are driving market growth, and what is their market share?

➠ What are the major growth drivers and restraints of the Japan CAR-T Cell Therapies market?

Stay informed with the latest industry insights-start your subscription now: https://www.datamintelligence.com/reports-subscription?kb

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.